cas 1802924-13-5|| where to buy tert-butyl N-(4-fluoro-2-methoxy-5-nitrophenyl)carbamate

Product Name:tert-butyl N-(4-fluoro-2-methoxy-5-nitrophenyl)carbamate

IUPAC Name:tert-butyl N-(4-fluoro-2-methoxy-5-nitrophenyl)carbamate

Packing Unit	Available Stock	Price($)
CM350166-100mg	in stock	ǤȎȎ
CM350166-250mg	in stock	ǵưȎ
CM350166-1g	in stock	ĽĽǵ

For R&D use only.

Inquiry Form

Chemical Name

CAS Number

Quantity*

Required Specifications*
(Assay %, Material Grade etc.)

Contact Name*

Contact Email*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 1802924-13-5 regularly via the above email.

Additional Notes

Verification code*

refresh

: CAS NO:1802924-13-5; Molecular Formula:C12H15FN2O5; Melting Point:-; Smiles Code:O=C(OC(C)(C)C)NC1=CC([N+]([O-])=O)=C(F)C=C1OC; Density:

: Catalog Number:CM350166; Molecular Weight:286.26; Boiling Point:; MDL No:; Storage:

: Benzenes; Benzene is an important organic compound with the chemical formula C6H6, and its molecule consists of a ring of 6 carbon atoms, each with 1 hydrogen atom. Benzene is a sweet, flammable, colorless and transparent liquid with carcinogenic toxicity at room temperature, and has a strong aromatic odor. It is insoluble in water, easily soluble in organic solvents, and can also be used as an organic solvent itself. The ring system of benzene is called benzene ring, and the structure after removing one hydrogen atom from the benzene ring is called phenyl. Benzene is one of the most important basic organic chemical raw materials. Many important chemical intermediates can be derived from benzene through substitution reaction, addition reaction and benzene ring cleavage reaction.

: Osimertinib; TAGRISSO (osimertinib) demonstrated overwhelming efficacy benefit for patients with unresectable, Stage III EGFR-mutated lung cancer in LAURA Phase III trial.
TAGRISSO (osimertinib) is a third-generation, irreversible EGFR-TKI with proven clinical activity in NSCLC, including against central nervous system metastases. It is the first and only EGFR TKI recommended by NCCN Guidelines as an adjuvant treatment option for completely resected stage IB-IIIA, stage IIIB (T3, N2) EGFRm (exon 19 deletion, exon 21 L858R mutation) NSCLC.

: Lazertinib; Johnson & Johnson announced new data from the Phase 2 PALOMA-2 study evaluating subcutaneous (SC) amivantamab combined with lazertinib as a first-line treatment in patients with advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or L858R mutations. These data showed a comparable response rate in patients treated with SC amivantamab and lazertinib compared to those treated with the intravenous (IV) formulation in the MARIPOSA study, which established the combination of amivantamab and lazertinib as superior to osimertinib. Lazertinib is an oral, third-generation, brain-penetrant EGFR tyrosine kinase inhibitor (TKI) that targets both the T790M mutation and activating EGFR mutations while sparing wild type-EGFR.
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.